IDRA-21 vs P21
A side-by-side research comparison of IDRA-21 and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | IDRA-21 | P21 |
|---|---|---|
| Full name | IDRA-21 (Benzothiadiazide AMPA PAM) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 262.7 Da | ~450 Da |
| Half-life | 8-12 hours (effects persist 48-72h) | 4-6 hours |
| Bioavailability | High (oral) | Moderate (crosses BBB) |
| Typical dose | 10-30 mg | 50-100 mcg/kg |
| Frequency | 2-3x per week | Daily |
| Route | Oral | Intranasal or Subcutaneous |
IDRA-21 reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.